Skip to main content

Table 4. Side effects in pooled cohorts

From: Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

 

After 1st dose

After 2nd dose

Mild

Moderate

Mild

Moderate

Severe

Local

     

 Pain, %

20

 

13

3

2

 Tenderness, %

10

 

7

1

 

Systemic

     

 Fever, %

  

3

1

 

 Headache, %

1

 

2

  

 Malaise, %

3

2

1

  

 Myalgia, %

1

  

1

 

 Chills, %

  

1

1

 
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us